Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
BDTX price, last 12 months
Key stats
- Previous close
- $1.43
- Open
- $1.44
- Day range
- $1.35 – $1.44
- 52-week range
- $1.31 – $4.06
- Volume
- 460.3K
- Avg volume (20 days)
- 737K
- Market cap
- $84.5M
Performance
Technicals and fundamentals
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $84.5M